Background: Complete cancer prevalence data in Europe have never been updated after the first estimates provided by the EUROPREVAL project and referred to the year 1993. This paper provides prevalence estimates for 16 majorcancers in Europe at the beginning of the year 2003.Patients and methods: We estimated complete prevalence by the completeness index method. We usedinformation on cancer patients diagnosed in 1978-2002 with vital status information available up to 31December 2003, from 76 European cancer registries.Results: About 11.6 millions of Europeans with a history of one of the major considered cancers were alive on1 January 2003. For breast and prostate cancers, about 1 out of 73 women and 1 out of 160 men were living with aprevious diagnosis of breast and prostate cancers, respectively. The demographic variations alone will increase thenumber of prevalent cases to nearly 13 millions in 2010.Conclusions: Several factors (early detection, population aging and better treatment) contribute to increase cancerprevalence and push for the need of a continuous monitoring of prevalence indicators to properly plan needs, resourceallocation to cancer and for improving health care programs for cancer survivors. Cancer prevalence should beincluded within the EU official health statistics. © The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Background: Complete cancer prevalence data in Europe have never been updated after the first estimates provided by the EUROPREVAL project and referred to the year 1993. This paper provides prevalence estimates for 16 majorcancers in Europe at the beginning of the year 2003.Patients and methods: We estimated complete prevalence by the completeness index method. We usedinformation on cancer patients diagnosed in 1978-2002 with vital status information available up to 31December 2003, from 76 European cancer registries.Results: About 11.6 millions of Europeans with a history of one of the major considered cancers were alive on1 January 2003. For breast and prostate cancers, about 1 out of 73 women and 1 out of 160 men were living with aprevious diagnosis of breast and prostate cancers, respectively. The demographic variations alone will increase thenumber of prevalent cases to nearly 13 millions in 2010.Conclusions: Several factors (early detection, population aging and better treatment) contribute to increase cancerprevalence and push for the need of a continuous monitoring of prevalence indicators to properly plan needs, resourceallocation to cancer and for improving health care programs for cancer survivors. Cancer prevalence should beincluded within the EU official health statistics.

Cancer prevalence estimates in Europe at the beginning of 2000

FERRETTI, Stefano
Membro del Collaboration Group
2013

Abstract

Background: Complete cancer prevalence data in Europe have never been updated after the first estimates provided by the EUROPREVAL project and referred to the year 1993. This paper provides prevalence estimates for 16 majorcancers in Europe at the beginning of the year 2003.Patients and methods: We estimated complete prevalence by the completeness index method. We usedinformation on cancer patients diagnosed in 1978-2002 with vital status information available up to 31December 2003, from 76 European cancer registries.Results: About 11.6 millions of Europeans with a history of one of the major considered cancers were alive on1 January 2003. For breast and prostate cancers, about 1 out of 73 women and 1 out of 160 men were living with aprevious diagnosis of breast and prostate cancers, respectively. The demographic variations alone will increase thenumber of prevalent cases to nearly 13 millions in 2010.Conclusions: Several factors (early detection, population aging and better treatment) contribute to increase cancerprevalence and push for the need of a continuous monitoring of prevalence indicators to properly plan needs, resourceallocation to cancer and for improving health care programs for cancer survivors. Cancer prevalence should beincluded within the EU official health statistics.
2013
Gatta, G; Mallone, S; van der Zwan, Jm; Trama, A; Siesling, S; Capocaccia, R; EUROCARE Working, Group; Ferretti, Stefano
File in questo prodotto:
File Dimensione Formato  
PIIS0923753419373119.pdf

accesso aperto

Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 131.8 kB
Formato Adobe PDF
131.8 kB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2154266
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 32
social impact